Edwards Lifesciences (NYSE:EW) CFO Sells $1,040,520.00 in Stock

Key Points

• CFO Scott Ullem sold 13,000 shares on April 9 at an average price of $80.04, generating $1,040,520 and reducing his direct stake by 24.67% to 39,699 shares; the sale was executed under a pre‑arranged Rule 10b5‑1 plan.
• Shares fell about 3.2% to $79.11 on heavy volume; the company recently missed EPS ($0.58 vs. $0.62) while beating revenue ($1.57B vs. $1.54B) and set Q1 2026 guidance of $0.700–0.760 EPS.
• Analyst sentiment is bullish with a MarketBeat average target of $95.96 and multiple firms raising targets, while institutional investors own roughly 79.46% of the stock.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) CFO Scott Ullem sold 13,000 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 3.2%

Shares of EW stock traded down $2.60 on Thursday, hitting $79.11. 5,469,089 shares of the company's stock traded hands, compared to its average volume of 4,117,509. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a one year low of $66.77 and a one year high of $87.89. The company's fifty day simple moving average is $81.53 and its 200 day simple moving average is $81.93. The stock has a market capitalization of $45.61 billion, a price-to-earnings ratio of 43.23, a P/E/G ratio of 2.13 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the business posted $0.59 EPS. Edwards Lifesciences's revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the stock. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth about $27,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth about $25,000. Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on EW. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, January 12th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their target price for the company from $90.00 to $100.00 in a report on Thursday, December 18th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Evercore reissued an "outperform" rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, Barclays reissued an "overweight" rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.